Overview

• US advanced therapies firm's Q1 revenue rose 30%, beating analyst expectations

• Gross margin improved to 72% in Q1, up from 69% a year earlier

• Company raised 2026 revenue guidance by $10 mln to $326-$336 mln

Outlook

• Vericel raises 2026 revenue guidance to $326-$336 mln from $316-$326 mln

• Company increases 2026 MACI revenue guidance to $282-$288 mln from $280-$286 mln

• Vericel lifts 2026 Burn Care revenue guidance to $44-$48 mln from $36-$40 mln

Result Drivers

• MACI GROWTH - MACI revenue rose 22% in Q1, with record biopsies, implants and surgeon participation

• BURN CARE SURGE - Burn Care revenue grew 91% in Q1, with Epicel revenue up 119%

• EXPENSES UP - Operating expenses increased due to higher headcount, MACI sales force expansion and new facility costs

Company press release: ID:nGNX7NwN6V

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.